Krishnamurthy Manan, Dhall Anjali, Sahoo Sarthak, Schultz Christopher W, Baird Michelle A, Desai Parth, Odell Jacob, Takahashi Nobuyuki, Nirula Michael, Zhuang Sophie, Huang Yue, Schroeder Brett, Zhang Yang, Thomas Maria Sebastian, Redon Christophe, Robinson Christina, Thang Lai, Ileva Lilia, Patel Nimit L, Kalen Joseph D, Varlet Alice-Anaïs, Zuela-Sopilniak Noam, Jha Ankita, Wangsa Darawalee, Butcher Donna, Morgan Tamara, Afzal Alyah N, Chari Raj, Baktiar Karim, Kumar Suresh, Pongor Lorinc, Difilippantonio Simone, Aladjem Mirit I, Pommier Yves, Jolly Mohit Kumar, Lammerding Jan, Sharma Ajit Kumar, Thomas Anish
Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Medical Scientist Training Program, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
bioRxiv. 2025 Jan 24:2024.10.07.617066. doi: 10.1101/2024.10.07.617066.
Metastasis is the leading cause of cancer-related deaths, yet its regulatory mechanisms are not fully understood. Small-cell lung cancer (SCLC) is the most metastatic form of lung cancer, with most patients presenting with widespread disease, making it an ideal model for studying metastasis. However, the lack of suitable preclinical models has limited such studies. We utilized rapid autopsy-derived tumors to develop xenograft models that mimic key features of SCLC, including histopathology, rapid and widespread development of metastasis to the liver, brain, adrenal, bone marrow, and kidneys within weeks, and response to chemotherapy. By integrating in vivo lineage selection with comprehensive bulk and single cell multiomic profiling of transcriptomes and chromatin accessibility, we identified critical cellular programs driving metastatic organotropism to the liver and brain, the most common sites of SCLC metastasis. Our findings reveal the key role of nuclear-cytoskeletal interactions in SCLC liver metastasis. Specifically, the loss of the nuclear envelope protein lamin A/C, encoded by the gene, increased nuclear deformability and significantly increased the incidence of liver metastasis. Human liver metastases exhibited reduced expression compared to other metastatic sites, correlating with poorer patient outcomes and increased mortality. This study introduces novel preclinical models for SCLC metastasis and highlights pathways critical for organ-specific metastasis, offering new avenues for the development of targeted therapies to prevent or treat metastatic disease.
转移是癌症相关死亡的主要原因,但其调控机制尚未完全明确。小细胞肺癌(SCLC)是肺癌中转移能力最强的类型,大多数患者就诊时已出现广泛病变,这使其成为研究转移的理想模型。然而,缺乏合适的临床前模型限制了此类研究。我们利用快速尸检获得的肿瘤建立了异种移植模型,该模型模拟了SCLC的关键特征,包括组织病理学、数周内迅速且广泛地转移至肝脏、脑、肾上腺、骨髓和肾脏,以及对化疗的反应。通过将体内谱系选择与转录组和染色质可及性的全面批量和单细胞多组学分析相结合,我们确定了驱动SCLC转移至肝脏和脑(SCLC最常见的转移部位)的关键细胞程序。我们的研究结果揭示了核-细胞骨架相互作用在SCLC肝转移中的关键作用。具体而言,由 基因编码的核膜蛋白核纤层蛋白A/C的缺失增加了核变形性,并显著增加了肝转移的发生率。与其他转移部位相比,人类肝转移灶中 表达降低,这与患者预后较差和死亡率增加相关。本研究引入了用于SCLC转移的新型临床前模型,并突出了器官特异性转移的关键途径,为开发预防或治疗转移性疾病的靶向疗法提供了新途径。